Modality
Nanobody
MOA
FcRni
Target
CDK4/6
Pathway
Tau
MigraineSLE
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Jul 2031
Phase 3Current
NCT06524340
23 pts·Migraine
2025-04→2031-07·Active
NCT08810929
2,728 pts·Migraine
2017-02→2030-01·Not yet recruiting
NCT05350755
1,742 pts·SLE
2024-10→TBD·Completed
+1 more trial
5,612 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-108mo awayPh3 Readout· Migraine
2030-01-283.8y awayPh3 Readout· Migraine
2031-07-085.3y awayPh3 Readout· Migraine
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2026-12-10 · 8mo away
Migraine
Ph3 Readout
2030-01-28 · 3.8y away
Migraine
Ph3 Readout
2031-07-08 · 5.3y away
Migraine
ActiveCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06524340 | Phase 3 | Migraine | Active | 23 | PFS |
| NCT08810929 | Phase 3 | Migraine | Not yet recr... | 2728 | SeizFreq |
| NCT05350755 | Phase 3 | SLE | Completed | 1742 | NT-proBNP |
| NCT06837124 | Phase 3 | Migraine | Terminated | 1119 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| Fixabrutinib | Verve | Phase 1 | RET |